当前位置: X-MOL 学术Lab Chip › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKey™ device for CTC enrichment
Lab on a Chip ( IF 6.1 ) Pub Date : 2021-07-12 , DOI: 10.1039/d1lc00546d
Kaylee Judith Smith 1 , Jessica Antoinette Jana 1 , Anna Kaehr 1 , Emma Purcell 1 , Tyler Opdycke 1 , Costanza Paoletti 2 , Laura Cooling 3 , Douglas H Thamm 4 , Daniel F Hayes 2 , Sunitha Nagrath 1, 2
Affiliation  

Circulating tumor cells (CTCs) are extremely rare cells shed from tumors into the blood stream. These cells can provide valuable information about their tumor of origin and direct treatment decisions to improve patient outcomes. Current technologies isolate CTCs from a limited blood volume and often require pre-processing that leads to CTC loss, making it difficult to isolate enough CTCs to perform in-depth tumor analysis. Many inertial microfluidic devices have been developed to isolate CTCs at high flow rates, but they typically require either blood dilution, pre-processing to remove red blood cells, or a sheath buffer rather than being able to isolate cells directly from whole blood. To decrease the need for pre-processing while increasing CTC yield, we developed an inertial device, the CTCKey™, to focus CTCs in whole blood at high throughput yielding a concentrated product stream enriched for CTCs. The CTCKey™ consists of two sections to create CTC enriched blood that can be further processed using any CTC isolation device to selectively isolate the CTCs. A thorough analysis was performed using the MCF7 breast cancer cell line spiked into bovine serum albumin (BSA) solutions of varying concentrations, as well as whole blood to characterize the focusing patterns of the CTCKey™. At the optimal flow rate of 2.4 mL min−1, the CTCKey™ reduces the CTC containing blood volume by 78%; the CTCs from 1 mL of blood are now in 0.22 mL of blood. The CTCKey's™ ability to concentrate CTCs from a large original blood volume to a smaller, highly concentrated volume enables a much greater blood volume to be interrogated by downstream isolation and characterization methods despite their low volume input limitations.

中文翻译:

使用用于 CTC 富集的微流控 CTCKey™ 装置以高流速惯性聚焦全血中的循环肿瘤细胞

循环肿瘤细胞 (CTC) 是从肿瘤脱落到血流中的极为罕见的细胞。这些细胞可以提供有关其起源肿瘤的宝贵信息,并指导治疗决策以改善患者的预后。当前技术从有限的血量中分离 CTC,并且通常需要导致 CTC 损失的预处理,因此难以分离足够的 CTC 以进行深入的肿瘤分析。许多惯性微流体装置已被开发用于以高流速分离 CTC,但它们通常需要血液稀释、预处理以去除红细胞或鞘缓冲液,而不是能够直接从全血中分离细胞。为了减少对预处理的需求,同时提高 CTC 产量,我们开发了一种惯性装置 CTCKey™,以高通量将 CTCs 集中在全血中,从而产生富含 CTCs 的浓缩产品流。CTCKey™ 由两个部分组成,用于产生富含 CTC 的血液,可以使用任何 CTC 分离装置进一步处理,以选择性地分离 CTC。使用掺入不同浓度牛血清白蛋白 (BSA) 溶液以及全血的 MCF7 乳腺癌细胞系进行彻底分析,以表征 CTCKey™ 的聚焦模式。在 2.4 mL/min 的最佳流速下 使用掺入不同浓度牛血清白蛋白 (BSA) 溶液以及全血的 MCF7 乳腺癌细胞系进行彻底分析,以表征 CTCKey™ 的聚焦模式。在 2.4 mL/min 的最佳流速下 使用掺入不同浓度牛血清白蛋白 (BSA) 溶液以及全血的 MCF7 乳腺癌细胞系进行彻底分析,以表征 CTCKey™ 的聚焦模式。在 2.4 mL/min 的最佳流速下-1,CTCKey™ 减少了 78% 的 CTC 含血量;来自 1 mL 血液的 CTC 现在存在于 0.22 mL 血液中。CTCKey 的™ 能够将 CTC 从大量原始血体积浓缩到更小、高度浓缩的体积,尽管它们的体积输入限制较低,但可以通过下游分离和表征方法检测更大的血体积。
更新日期:2021-07-29
down
wechat
bug